{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Design": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Participants": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Intervention": {
        "score": 2,
        "evidence": "compares the efficacy and safety of palonosetron and ondansetron"
      },
      "Objective": {
        "score": 1,
        "evidence": "To establish evidence for best clinical practices, this meta-analysis compares the efficacy and safety of palonosetron and ondansetron in preventing PONV"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "reported the efficacy (nausea and vomiting) at postoperative time points, namely T1 (0\u20132 hours), T2 (0\u20136 hours), T3 (12\u201324 hours), T4 (24\u201348 hours), and T5 (24\u201372 hours)"
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "Nineteen randomised controlled trials were included"
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "Pooled risk ratio (RR) revealed that patients receiving palonosetron were significantly less likely to develop nausea [0\u20132 h, RR = 0.82 (95% confidence interval (CI): 0.50, 1.34)"
      },
      "Harms": {
        "score": 1,
        "evidence": "The safety profiles of palonosetron and ondansetron were comparable"
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 10,
    "max_score": 25
  },
  "model": "gpt-4o"
}